Synchron Closes $275M Series D to Accelerate Stentrode BCI Commercialization

Synchron, the New York-based brain-computer interface company behind the endovascular Stentrode device, announced today the close of a $275 million Series D funding round, marking one of the largest single raises in BCI history. The round was led by Khosla Ventures, with participation from existing investors including ARCH Venture Partners, NEA, and a new strategic commitment from Medtronic, signaling growing interest from established medical device players in the BCI space.

The Stentrode distinguishes itself from competing implants by requiring no open-brain surgery. Instead, it is delivered through the jugular vein and lodged in a blood vessel adjacent to the motor cortex, where it records neural signals and transmits them wirelessly to external devices. The approach has attracted significant clinical attention as a lower-risk alternative to cortical electrode arrays, and the company has been conducting a pivotal US trial since late 2024 with participants diagnosed with amyotrophic lateral sclerosis and severe paralysis.

Synchron CEO Tom Oxley said the fresh capital will be directed toward three priorities: scaling US manufacturing capacity at the company's Pittsburgh facility, expanding the pivotal COMMAND trial to additional sites across the United States and Australia, and pursuing a De Novo regulatory submission with the FDA expected in the first quarter of 2027. The company also confirmed it intends to pursue CE Mark approval in the European Union concurrently.

The funding arrives amid intensifying competition in the implantable BCI sector. Neuralink received FDA Breakthrough Device designation for a second indication earlier this year, while Paradromics and Precision Neuroscience continue to advance their own cortical array platforms. Analysts at SVB Securities estimate the addressable market for paralysis-focused BCIs could reach $4.2 billion annually by 2032, a projection that helps explain why venture and strategic capital continues to flow into the space despite long regulatory timelines.

Medtronic's participation as a strategic investor is particularly notable. The company, which dominates the neuromodulation market through its deep brain stimulation and spinal cord stimulator franchises, has previously signaled interest in acquiring or partnering with BCI developers as those technologies mature toward commercial readiness. Neither party disclosed the terms of any potential future commercial agreement.

Synchron currently has more than 10 patients implanted with the Stentrode across its early feasibility and pivotal studies, with published results showing stable signal quality beyond 24 months post-implant — a data point the company expects will feature prominently in its regulatory filings.